Cargando…

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents

The incidence of melanoma is rising. The primary initial treatment for melanoma continues to be wide local excision of the primary tumor and affected lymph nodes. Exceptions to wide local excision include cases where surgical excision may be cosmetically disfiguring or associated with increased morb...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Mohammad K, Khan, Niloufer, Almasan, Alex, Macklis, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176173/
https://www.ncbi.nlm.nih.gov/pubmed/21949607
http://dx.doi.org/10.2147/OTT.S20257
_version_ 1782212187621687296
author Khan, Mohammad K
Khan, Niloufer
Almasan, Alex
Macklis, Roger
author_facet Khan, Mohammad K
Khan, Niloufer
Almasan, Alex
Macklis, Roger
author_sort Khan, Mohammad K
collection PubMed
description The incidence of melanoma is rising. The primary initial treatment for melanoma continues to be wide local excision of the primary tumor and affected lymph nodes. Exceptions to wide local excision include cases where surgical excision may be cosmetically disfiguring or associated with increased morbidity and mortality. The role of definitive or adjuvant radiotherapy has largely been relegated to palliative measures because melanoma has been viewed as a prototypical radiotherapy-resistant cancer. However, the emerging clinical and radiobiological data summarized here suggests that many types of effective radiation therapy, such as radiosurgery for melanoma brain metastases, plaque brachytherapy for uveal melanoma, intensity modulated radiotherapy for melanoma of the head and neck, and adjuvant radiotherapy for selected high-risk, node-positive patients can improve outcomes. Similarly, although certain chemotherapeutic agents and biologics have shown limited responses, long-term control for unresectable tumors or disseminated metastatic disease has been rather disappointing. Recently, several powerful new biologics and treatment combinations have yielded new hope for this patient group. The recent identification of several clinically linked melanoma gene mutations involved in mitogen-activated protein kinase (MAPK) pathway such as BRAF, NRAS, and cKIT has breathed new life into the drive to develop more effective therapies. Some of these new therapeutic approaches relate to DNA damage repair inhibitors, cellular immune system activation, and pharmacological cell cycle checkpoint manipulation. Others relate to the investigation of more effective targeting and dosing schedules for underutilized therapeutics, such as radiotherapy. This paper summarizes some of these new findings and attempts to give some context to the renaissance in melanoma therapeutics and the potential role for multimodality regimens, which include certain types of radiotherapy as aids to locoregional control in sensitive tissues.
format Online
Article
Text
id pubmed-3176173
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31761732011-09-26 Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents Khan, Mohammad K Khan, Niloufer Almasan, Alex Macklis, Roger Onco Targets Ther Review The incidence of melanoma is rising. The primary initial treatment for melanoma continues to be wide local excision of the primary tumor and affected lymph nodes. Exceptions to wide local excision include cases where surgical excision may be cosmetically disfiguring or associated with increased morbidity and mortality. The role of definitive or adjuvant radiotherapy has largely been relegated to palliative measures because melanoma has been viewed as a prototypical radiotherapy-resistant cancer. However, the emerging clinical and radiobiological data summarized here suggests that many types of effective radiation therapy, such as radiosurgery for melanoma brain metastases, plaque brachytherapy for uveal melanoma, intensity modulated radiotherapy for melanoma of the head and neck, and adjuvant radiotherapy for selected high-risk, node-positive patients can improve outcomes. Similarly, although certain chemotherapeutic agents and biologics have shown limited responses, long-term control for unresectable tumors or disseminated metastatic disease has been rather disappointing. Recently, several powerful new biologics and treatment combinations have yielded new hope for this patient group. The recent identification of several clinically linked melanoma gene mutations involved in mitogen-activated protein kinase (MAPK) pathway such as BRAF, NRAS, and cKIT has breathed new life into the drive to develop more effective therapies. Some of these new therapeutic approaches relate to DNA damage repair inhibitors, cellular immune system activation, and pharmacological cell cycle checkpoint manipulation. Others relate to the investigation of more effective targeting and dosing schedules for underutilized therapeutics, such as radiotherapy. This paper summarizes some of these new findings and attempts to give some context to the renaissance in melanoma therapeutics and the potential role for multimodality regimens, which include certain types of radiotherapy as aids to locoregional control in sensitive tissues. Dove Medical Press 2011-08-09 /pmc/articles/PMC3176173/ /pubmed/21949607 http://dx.doi.org/10.2147/OTT.S20257 Text en © 2011 Khan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Khan, Mohammad K
Khan, Niloufer
Almasan, Alex
Macklis, Roger
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
title Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
title_full Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
title_fullStr Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
title_full_unstemmed Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
title_short Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
title_sort future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176173/
https://www.ncbi.nlm.nih.gov/pubmed/21949607
http://dx.doi.org/10.2147/OTT.S20257
work_keys_str_mv AT khanmohammadk futureofradiationtherapyformalignantmelanomainaneraofnewermoreeffectivebiologicalagents
AT khanniloufer futureofradiationtherapyformalignantmelanomainaneraofnewermoreeffectivebiologicalagents
AT almasanalex futureofradiationtherapyformalignantmelanomainaneraofnewermoreeffectivebiologicalagents
AT macklisroger futureofradiationtherapyformalignantmelanomainaneraofnewermoreeffectivebiologicalagents